Search research articles
Contact Us
Filters
Showing results (101-110 of 266) with videos related to
Page
of 27
Sort By:
Haematologica
|
February 14, 2007
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience
Hendrik-Tobias Arkenau, Geoff Chong, David Cunningham, et al.
Investigational New Drugs
|
March 5, 2013
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer
Joanne Brady, Pippa Corrie, Ian Chau, et al.
Leukemia & Lymphoma
|
November 5, 2021
Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment
Aislinn Macklin-Doherty, Michael Jones, Penny Coulson, et al.
BMC Cancer
|
April 10, 2024
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.
BMC Cancer
|
January 22, 2015
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience
Khurum Khan, Clare Peckitt, Francesco Sclafani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2004
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer
Rohit Lal, James Dickson, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2002
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer
Nick Maisey, Ian Chau, David Cunningham, et al.
Expert Review of Anticancer Therapy
|
August 19, 2017
Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
Eva Segelov, Florian Lordick, David Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial
Alicia F C Okines, Sue E Ashley, David Cunningham, et al.
Current Oncology (Toronto, Ont.)
|
September 26, 2025
Clinical and Molecular Profiling of Colorectal Cancer: A Comprehensive Cohort Study of BRAF-Mutated Cases from a Tertiary Centre
Julia Freckelton, Justin Mencel, Iris Levink, et al.
Page
of 27
Search research articles
Search
Showing results (101-110 of 266) with videos related to
Sort By:
Page
of 27
Haematologica
|
February 14, 2007
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience
Hendrik-Tobias Arkenau, Geoff Chong, David Cunningham, et al.
Investigational New Drugs
|
March 5, 2013
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer
Joanne Brady, Pippa Corrie, Ian Chau, et al.
Leukemia & Lymphoma
|
November 5, 2021
Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment
Aislinn Macklin-Doherty, Michael Jones, Penny Coulson, et al.
BMC Cancer
|
April 10, 2024
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.
BMC Cancer
|
January 22, 2015
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience
Khurum Khan, Clare Peckitt, Francesco Sclafani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2004
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer
Rohit Lal, James Dickson, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2002
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer
Nick Maisey, Ian Chau, David Cunningham, et al.
Expert Review of Anticancer Therapy
|
August 19, 2017
Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
Eva Segelov, Florian Lordick, David Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial
Alicia F C Okines, Sue E Ashley, David Cunningham, et al.
Current Oncology (Toronto, Ont.)
|
September 26, 2025
Clinical and Molecular Profiling of Colorectal Cancer: A Comprehensive Cohort Study of BRAF-Mutated Cases from a Tertiary Centre
Julia Freckelton, Justin Mencel, Iris Levink, et al.
Page
of 27